Context: We previously identified 2 Finnish families with dominantly inherited, low-turnover osteoporosis caused by mutations in WNT1 or PLS3.
R ecent advancements in genetic methodology have greatly increased our understanding of the genetic architecture of osteoporosis (1) . Several monogenic forms of osteoporosis have been described (2) . Their clinical features and characteristics at the bone tissue level are variable and thus underscore the importance of individually tailored treatment to take into account the genetic and molecular pathogenesis of skeletal fragility in an affected individual.
Our family-based studies led to the identification of 2 large Finnish families with dominantly inherited, monogenic, earlyonset osteoporosis caused by a missense mutation in Wingless + int1 (WNT1), c.652T.G (p.Cys218Gly) (3) , and a splice mutation in plastin 3 (PLS3), c.73-24T.A(4). The exact mechanisms whereby WNT1 and PLS3 mutations affect bone health are unclear. We showed that the heterozygous Cys218Gly WNT1 mutation impaired WNT/ b-catenin signaling, confirming that WNT1 is an important ligand for the Wnt signaling pathway in the regulation of bone mass (3) . PLS3 is likely to play a role in osteocyte dendrite function and skeletal mechanosensing (4) . Affected family members present severe and progressive osteoporosis with low bone mineral density (BMD), peripheral fractures, and multiple compression fractures, especially in the thoracic spine (3, 4) . Although bone turnover markers in serum have been rather normal, previous double-labeled iliac crest bone biopsies have shown severe low-turnover osteoporosis in both pedigrees (3, 4) . Thus, in these patients, antiresorptive treatment does not seem to be the most logical option to improve bone strength and prevent fractures. Instead, an anabolic agent such as teriparatide (PTH 1-34), which has been shown to decrease the incidence of vertebral and nonvertebral fractures in postmenopausal osteoporosis (5) , could be adopted as a first-line therapy provided that the mutations underlying osteoporosis do not prevent its action on bone cells.
The present pilot study was undertaken to evaluate whether patients with low-turnover osteoporosis due to WNT1 or PLS3 mutations respond to teriparatide treatment and, second, whether such patients show beneficial effects similar to those previously described in pre-and postmenopausal women or men with osteoporosis. We present the outcome of teriparatide treatment in the 2 mutation groups together because they both represent low-turnover osteoporosis and because the patient number was very low in each group. Acknowledging the lack of statistical power resulting from the small sample size, we explored potential differences in response to osteoanabolic treatment that could be attributed to differences in the pathogenic mechanisms underlying the osteoporosis of patients with WNT1 and PLS3 mutations.
Materials and Methods

Subjects
Adult members of the 2 recently described (3, 4) Finnish families with osteoporosis (lumbar spine or hip BMD T-score # 22.5 prior to the study) and a verified mutation in WNT1 or PLS3 were offered the opportunity to participate in the study. Exclusion criteria for the current study were age , 18 years, previous teriparatide treatment, and general contraindications for teriparatide treatment (hypercalcemia, pregnancy, severe renal failure, elevated serum alkaline phosphatase, other bone disease, malignancy, or previous radiotherapy). Six (3 with WNT1 and 3 with PLS3 mutation) of 12 potential patients were recruited, and all of the participants provided written informed consent. The study was approved by the Research Ethics Committee of the Helsinki University Central Hospital and performed according to the ethical principles defined in the Declaration of Helsinki. The study protocol was registered in ClinicalTrials.gov (ID: NCT01360424).
Study design
This was a prospective, longitudinal, uncontrolled, experimental study. Clinical assessment, lumbar spine (LS), femoral neck (FN), and total hip (TH) BMD by dual energy X-ray absorptiometry (DXA), distal radius peripheral quantitative computed tomography (pQCT), and lumbar and thoracic spine X-rays were performed at baseline, 12 months, and 24 months. Paired double-labeled iliac crest biopsies for histomorphometric and mCT analyses were taken at baseline and at 24 months. Serum samples were collected at baseline and at 3, 6, 12, and 24 mo. Dietary intake of vitamin D and calcium was assessed with a questionnaire at baseline and at 12 and 24 months.
Intervention
The patients were treated with daily subcutaneous administration of teriparatide at a dose of 20 mg (Forsteo ® ; Eli Lilly, Indianapolis, IN) for 24 months. In addition, all of the patients received 20 mg of vitamin D 3 and 1 g of calcium daily. Ongoing bisphosphonate (BP) treatments were discontinued.
Laboratory assessments
Blood samples were obtained between 8:00 and 10:00 AM after an overnight fast. Serum 25-hydroxyvitamin D, osteocalcin, procollagen type 1 amino-terminal propeptide (S-P1NP), and cross-linked C-telopeptide of type I collagen (S-CTX) were measured using chemiluminescence immunoassay methods developed for the automated analyzer IDS-iSYS (Immunodiagnostic Systems, Boldon, UK). Serum tartrate-resistant acid phosphatase 5b (S-Tracp5b) activity was measured by an immunoextraction method with BoneTRAP (Immunodiagnostic Systems, Boldon, UK). Serum sclerostin (S-Scl) was measured using a manual enzyme-linked immunosorbent assay method (Biomedica, Vienna, Austria). Ionized calcium was analyzed with an ABL 825 blood-gas analyzer (Radiometer Medical, Bronshoj, Denmark).
DXA, pQCT, and radiography
BMD at the lumbar spine and hip was measured by DXA using a Lunar Prodigy Advanced DXA (GE Healthcare, Madison, WI) or Hologic Discover A densitometer (Hologic, Waltham, MA). Each patient was measured using the same densitometer and standardized protocol at each time point. pQCT (XCT-2000, software version 6.20; Stratec, Pforzheim, Germany) was used to measure volumetric BMD (vBMD) and bone geometry at the nondominant radius, as described previously (6) . Briefly, the radius was measured at the distal metaphyseal (4%) and middiaphyseal (50%) (data not shown) sites. The measurement site was determined by means of a scout view. The scans were analyzed using the radius2S macro provided by the manufacturer (Stratec, Pforzheim, Germany), as described previously (6) . The standard anteroposterior and lateral lumbar and thoracic spine X-rays were made and analyzed for vertebral fractures by a specialized radiologist. Each patient's vertebrae were graded as normal (normal height) or as mildly, moderately, or severely deformed (a decrease in height of approximately 20% to 25%, 26% to 40%, or more than 40%, respectively).
Histomorphometric and mCT analyses of paired iliac crest biopsies
Transiliac bone specimens were obtained from the anterior iliac spine using a manual drill with a trephine of 7.5-mm inner diameter (Rochester Bone Biopsy; Medical Innovations International, Rochester, MN) after a double-labeling with 500 mg of oral tetracycline 3 times per day in a 2:10:2-day sequence (7) . To ensure adequate tetracycline absorption, patients refrained from consuming dairy products or taking supplemental calcium during tetracycline labeling periods. The first biopsy was taken at baseline from the left and the second at 24 months from the right iliac crest. The specimens were placed in 70% ethanol, then dehydrated and embedded in polymethyl methacrylate. Static histomorphometric parameters were evaluated in undecalcified 5-mm sections treated with toluidine blue. Tetracycline labeling was assessed in unstained 10-mm sections. Primary bone histomorphometric parameters were assessed in trabecular bone under 3200 magnification using the OsteoMeasure ® system (OsteoMetrics, Decatur, GA). Mineralized bone was defined by dark blue staining areas; pale-blue seams at least 1.5 mm in width were included in measurements of osteoid. Derived indices were calculated according to standard formulae (8) . Nomenclature and abbreviations follow the recommendations of the American Society for Bone and Mineral Research (8) . For adipocyte number, the entire 5-um section with intact marrow/cancellous bone compartment was analyzed with a 310 objective using the OsteoMeasure ® system. The number of adipocytes was measured and divided by total tissue area, including bone marrow and bone tissue, to determine adipocyte number per square millimeters.
The iliac crest bone samples were scanned using a SkyScan 1072 mCT scanner (SkyScan, Kontich, Belgium). The samples were inserted into a tight paraffin-sealed tubular plastic holder. The following parameters were used for the scanning: voxel resolution, 13.96 mm; x-ray tube potential, 61 kVp; current, 148 mA; and integration time, 3900 ms. An internal 0.25-mm aluminum filter was applied. The object was rotated in 0.45-degree steps (total, 182.45 degrees). Cross-sectional image reconstruction (Nrecon 1.6.9; SkyScan) was performed with the following parameters: dynamic range attenuation coefficients, 0.010 to 0.120; smoothing level, 2; beam-hardening reduction, 85%; and ring artifact reduction level, 7. Perpendicular orientation of the transaxial biopsy images of trabecular bone relative to the inner surface of the outer cortical bone of the iliac crest was ascertained by Dataviewer 1.4.4 program (Skyscan), thus reducing the effective resolution to 27.9 mm. Analysis and modeling were performed using CTan 1.13.2.1 software (Skyscan). Cross-sectional images were binarized using an attenuation coefficient range of 0.02118 to 0.11906. In the trabecular bone, a cylinder-shaped volume of interest having a diameter of 5.5 mm and length of 50 layers (1.396 mm) was defined. For cortical bone analysis, a square-form (3.99 3 3.99 mm) stack of 10 layers (0.279 mm) was defined, ending 2 layers below the inner surface of the outer cortical bone of the iliac crest. BMD calibration was performed with ceramic standards.
Results
A total of 6 patients were recruited for the study; 3 were heterozygous for the c.652T.G (p.Cys218Gly) WNT1 mutation (3), and 1 was heterozygous and 2 were hemizygous for the c.73-24T.A PLS3 splice mutation, which causes a frameshift and premature termination of mRNA translation (p.Asp25Alafs*17) (4). Two patients were women (1 premenopausal and 1 postmenopausal), and 4 were men. The median age was 54 years (range, 37 to 72 years). All patients had sustained spinal compression fractures. Five had received prior BP treatment. All patients showed sufficient (. 50 nmol/L) serum 25-hydroxyvitamin D and normal serum ionized calcium levels. The baseline characteristics are presented in detail in Table 1 .
Fractures
There were no new clinical fractures during the 24-month intervention. Patient 1 WNT1 showed a mild new morphometric L1 vertebral end-plate compression at 24 months.
Bone turnover markers
All patients showed significant increases in serum bone formation markers P1NP and osteocalcin during the first 3 to 6 months of treatment (90% to 397% and 50% to 280%, respectively; Fig. 1 ). The markers stayed above baseline throughout the 24 months of intervention. Serum bone resorption markers CTX and Tracp5b increased as well (Fig. 1) . Interestingly, the increases in Tracp5b were only modest (20% to 68%) in comparison with those in CTX (58% to 457%); both remained elevated throughout follow-up. Sclerostin levels fluctuated from 228% to 58% from baseline without any consistency (Fig. 1) .
Bone characteristics in DXA and pQCT
In all but 1 patient (2 WNT1 ), LS BMD increased from 5.2% to 7.9% after 24 months of treatment (Fig. 2) . FN BMD increased between 2.6% and 7.8% in 4 patients during the 24 months of treatment, but did not change in 2 patients (1 WNT1 , 3 WNT1 ; Fig. 2 ). TH BMD increased only from 1.0% to 2.6% in 4 patients, stayed unchanged in 1 patient (5 PLS3 ), and decreased 3.7% in 1 patient (1 WNT1 ; Fig. 2 ). Two of the 5 patients with prior BP treatment showed temporary FN BMD decreases of press.endocrine.org/journal/jcem1.8% and 4.3% during the first 12 months of treatment. Patient 4 PLS3 with no history of prior BP treatment and the only female patient with a PLS3 mutation seemed to benefit most consistently in terms of BMD at different measurement sites. In pQCT measurements, available for 5 patients, distal radius cortical vBMD decreased in all by 5.4% to 26.1% during the 24-month intervention (Table 2) . Trabecular vBMD increased 2.3% to 37.9% in 4 and decreased 26.3% in 1 patient (1 WNT1 ). During the 24 months, total distal radius vBMD decreased in 4 patients (2.8% to 26.2%) but increased 4.5% in 1 patient. Total, trabecular, and cortical cross-sectional area all increased in 4 patients (1 WNT1 , 2 WNT1 , 4 PLS3 , 5 PLS3 ), but decreased in 1 patient (6 PLS3 ; Table 2 ).
Histomorphometric analyses
Histomorphometry of the iliac crest biopsies showed 106% to 516% increases in osteoid surface and 123% to 938% increases in osteoid volume in 4 of 6 patients (Table 3 ). In 2 patients (4 PLS3 and 6 PLS3 ), osteoid surface and volume decreased (26% to 62% and 23% to 70%, respectively). Five of 6 patients showed an increase in osteoid thickness of 14% to 100%. Osteoid surface, volume, and thickness increased more consistently in patients with WNT1 mutation than in those with PLS3 mutation (Table 3) . Interestingly, the eroded surface decreased 44% to 100% in all 6 patients. However, osteoclast surface decreased in 3 and increased in 2 patients. Tetracycline double labels were detectable in only 3 of 6 patients at baseline, in line with low bone turnover. Teriparatide treatment did not enhance the number of patients with double labeling at 24 months; thus, dynamic histomorphometric parameters were available only for 3 patients. Among them, patient 1 WNT1 was the only patient showing an increase in mineral apposition rate, mineralizing surface, and bone formation rate. One of the 3 patients without double labels at baseline showed Abbreviations: S-Ca-Ion, serum ionized calcium; S-CTX, serum cross-linked C-telopeptide of type I collagen; S-Oca, serum osteocalcin; S-P1NP, serum procollagen type 1 amino-terminal propeptide; S-Scl, serum sclerostin; S-Tracp5b, serum tartrate-resistant acid phosphatase 5b; S-25OHD, serum 25-hydroxyvitamin D.
them after 24 months of treatment, but 1 with double labels at baseline no longer showed them at 24 months. Adipocyte number increased in all 5 patients with available data; the increases seemed to be higher in patients with WNT1 mutation than in those with PLS3 mutation [ Table 3 ; Fig. 3(A) and 3(B) ].
mCT analyses
The results of mCT analyses of iliac crest bone biopsies were variable and showed heterogeneous findings between individuals, without any clear effect of the genotype. Bone volume fraction increased only in 2 patients (3 WNT1 and 6 PLS3 ) and decreased in the others (Supplemental Table 1 ). No consistent trends were found for trabecular number, thickness, and separation, which all increased in 3 and decreased in 3 patients (Supplemental Table 1 ), as did structure model index. Connective density increased in 2 patients (2 WNT1 and 4 PLS3 ), but decreased in 2 (1 WNT1 and 3 WNT1 ) and did not change in 2 patients (5 PLS3 and 6 PLS3 ). Cortical thickness increased only in 1 patient (4 PLS3 ) and decreased in the others during the 24-month treatment (Supplemental Table 1 ). Structure model index decreased 13% to 42% in 3 of 6 patients.
Discussion
In treatment of postmenopausal and idiopathic premenopausal osteoporosis, 20 mg/d teriparatide has been shown to induce up to twofold to threefold increases in bone formation markers such as serum P1NP, alkaline phosphatase, and osteocalcin during the first 6 months of treatment (9) (10) (11) (12) . Bone resorption markers such as serum CTX have increased to a lesser extent (9, 10, 12) . In men, the marker changes have been same directional, but less pronounced (13) . Although serum sclerostin levels are decreased in primary hyperparathyroidism (14) , no consistent changes have been observed in press.endocrine.org/journal/jcemteriparatide-treated patients (15) . In previous studies, prior BP use has not prevented the response of bone turnover markers to teriparatide (11) . In line with the previous findings (16), we observed a greater increase in serum CTX than Tracp5b (a marker of osteoclast number) levels. Thus, in respect to bone turnover markers, all 6 patients responded to teriparatide treatment in accordance with expectations and independently of their diseasecausing gene mutation. Previous studies have documented increases in BMD of around 10% to 13% in LS, 3% to 8% in FN, and 3% to 6% in TH in both postmenopausal women with osteoporosis and premenopausal women with idiopathic osteoporosis undergoing 18 to 24 months of teriparatide treatment (5, 9, 10, 12, 17) , whereas the magnitude of response to treatment may be attenuated in men with idiopathic or hypogonadal osteoporosis (13) . Prior BP treatment may interact with teriparatide therapy; an early decrease in FN and TH BMD has been observed during the first 6 months of treatment in postmenopausal women (17) ; however, early decreases in BMD reverted by 18 months, and total BMD has been shown to be comparable between BP users vs BP-naïve patients after 24 months of teriparatide. Increases of 5% to 8% in LS BMD, but variable responses in FN and TH BMD, in the current study suggest that the magnitude of response to teriparatide therapy in patients with WNT1 and PLS3 mutations may be inferior to the response observed in other osteoporotic disease states.
In contrast to observed increases in trabecular bone density, teriparatide has been associated with decreases in cortical bone density (i.e., at the distal radius) in postmenopausal (18) (19) (20) but not premenopausal (21) women with osteoporosis, and there are no data in the literature that address whether prior BP treatment may modify the effect of teriparatide on the distal radius. In the current study, all 5 patients with available pQCT data showed 5% to 26% decreases in cortical vBMD at 24 months, suggesting a treatment response similar to that of postmenopausal women in previous cohorts.
Histological studies have suggested that teriparatide increases both bone formation and resorption in cancellous and cortical bone (22, 23) . However, there are only few longitudinal histomorphometric studies with paired iliac crest bone biopsies. In 51 postmenopausal women, Jiang et al. (24) showed teriparatide to increase bone volume and to decrease marrow star volume, an index of trabecular connectivity, whereas no significant changes were seen in the indices of cancellous bone remodeling, resorption, formation, or labeling after 18 months. In 10 postmenopausal women treated with teriparatide for 24 months, Dempster et al. (25) found no significant changes in static or dynamic indices for cancellous bone from 6 to 24 months of treatment, but baseline biopsies were not available. By contrast, Stepan et al. (26) showed a significant increase in bone formation rate (osteoid surface and activation frequency) and in bone resorption rate (eroded surface and osteoclast surface) in 45 postmenopausal women (29 pretreated with alendronate, 16 treatment naïve) after 24 months of teriparatide treatment, regardless of whether patients had received prior antiresorptive therapy. However, patients without adequate double labels were excluded from the analyses. In 19 premenopausal women with idiopathic osteoporosis, Cohen et al. (12) showed 18 months of treatment to increase cancellous wall width and to decrease osteoclast number, but not to increase bone formation rate. In our study, double labels were detectable in only 3 patients at baseline, in line with low bone turnover. In these 3 patients only 1 (1 WNT1 ) showed a marked increase in dynamic indices of bone formation at 24 months. However, 4 patients showed an increase in osteoid surface, volume, and thickness after 24 months of treatment, reflecting enhanced bone formation. In terms of these 3 osteoid parameters, the patients with the WNT1 mutation responded more consistently to treatment than did those with the PLS3 mutation. Together, these data suggest that teriparatide may induce a mineralization defect at the few remodeling sites turning over in patients with the WNT1 mutation, and biopsies obtained at an earlier time point (i.e., after 6 months of treatment) may have shed additional light on this question. Contrary to the previous findings of Stepan et al. (26) , eroded surface decreased by 44% to 100% in all 6 patients in the current study. This intriguing finding suggests that Wnt signaling may be essential for PTH-mediated bone resorption, although not for bone formation, in vivo and additional studies are needed to further evaluate the pathways involved in bone remodeling.
Previous studies have demonstrated that bone marrow adiposity is higher in premenopausal women with idiopathic osteoporosis than in healthy controls and, in contrast to the general population, that adiposity in these patients has no relationship to bone microstructure or remodeling (27) . Moreover, teriparatide treatment appears to decrease adipocyte area, perimeter, and volume in this population and in women with postmenopausal osteopenia (12, 28) . By contrast, teriparatide increased adipocyte density in all patients in the current study, and the effect seemed to be more pronounced in individuals with WNT1 mutation. Because Wnt signaling is known to inhibit adipogenesis (29), our findings suggest that the adipocyte lineage may be more heavily affected by the WNT1 mutation than is the osteoblast lineage.
Longitudinal mCT studies of paired iliac crest bone biopsy specimens in postmenopausal (24, 30, 31) and idiopathic premenopausal (12) osteoporosis have yielded variable results, and no data in the literature assess whether prior BP therapy alters response to teriparatide. In general, however, most studies suggest that teriparatide may increase bone volume (12, 31) , trabecular number (12), The arrows indicate the expected effect of teriparatide treatment on the basis of longitudinal studies in women with postmenopausal osteoporosis (18) (19) (20) .
Abbreviations: BL, baseline; BMC, bone mineral content; CSA, cross-sectional area; ND, not done.
doi: 10.1210/jc.2016-2423 press.endocrine.org/journal/jcemstandard deviation of trabecular separation (31), connective density (24, 31) , and cortical thickness (24, 30) while decreasing trabecular separation (12) and structure model index (24) . In the current study, cortical thickness decreased in 5 of 6 patients with WNT1 or PLS3 mutations, in contrast with previous data (24, 30) . As emphasized by Chappard et al. (32) , mCT parameters carry relatively large individual side-to-side variation between the left and right crest, which might explain these conflicting results, given that the baseline biopsy was taken from the left crest and the second biopsy from the right crest. Alternatively, it is possible that the edge detection algorithms used in the mCT (and pQCT) method may underestimate the quantity of teriparatide-induced, nonfully mineralized new bone (21) .
No clinical fractures were observed during the course of the study. The 1 new mild morphometric vertebral endplate compression fracture during treatment occurred in a patient with clear responses in bone turnover markers, LS BMD, and histomorphometric parameters.
Our study has several limitations. The number of participants was small, and they presented 2 different monogenetic forms of osteoporosis with different underlying pathogenetic mechanisms. Thus, we were unable to draw firm conclusions about differences in treatment response between the genotypes. However, we were able to recruit 50% of the recognized adult Finnish patients with these rare forms of osteoporosis, which we believe to be a high recruitment rate for a study with even invasive paired bone biopsies. Second, all but 1 of the patients were prior BP users, which obviously modified the results. Third, we did not have a placebo group or a teriparatide-treated control group with common forms of osteoporosis to obtain comparative data. Fourth, the timing of a bone biopsy at an earlier time point (i.e., 6 months) may have provided additional information on the effect of teriparatide on bone. In a study of 14 postmenopausal women, several parameters of bone formation were higher after 6 vs 18 months of treatment with teriparatide, but only 2 women had pairwise Abbreviations: AdN, adipocyte number (per mm 2 of tissue area); BFR, bone formation rate; BL, baseline; BS, bone surface; BV, bone volume; ES, eroded surface; MAR, mineral apposition rate; MS, mineralizing surface; N/A, not available; ObS, osteoblast surface; OcS, osteoclast surface; OS, osteoid surface; OTh, osteoid thickness; OV, osteoid volume; TbN, trabecular number; TbSp, trabecular separation; TbTh, trabecular thickness; TV, tissue volume.
biopsies at both time points (33) . Conversely, it was clear that if we wanted to ensure retention of the participants in the study, we could not include 3 biopsies in the protocol.
In conclusion, patients with WNT1 or PLS3 mutationrelated low-turnover osteoporosis responded to teriparatide 20 mg per day for 24 months. Changes in circulating bone turnover markers and DXA and pQCT measurements of BMD were most pronounced; these findings were similar to those reported in postmenopausal women and men with osteoporosis. Histomorphometric and mCT studies gave less consistent findings that were often discordant with previous observations. Whether the changes observed in bone metabolism and structure translate into reductions in fracture risk remains to be evaluated.
